Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
25.26
+1.30 (5.43%)
At close: May 12, 2025, 4:00 PM
25.33
+0.07 (0.27%)
After-hours: May 12, 2025, 6:42 PM EDT
Summit Therapeutics Employees
Summit Therapeutics had 159 employees as of December 31, 2024. The number of employees increased by 54 or 51.43% compared to the previous year.
Employees
159
Change (1Y)
54
Growth (1Y)
51.43%
Revenue / Employee
n/a
Profits / Employee
-$1,514,182
Market Cap
18.76B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 159 | 54 | 51.43% |
Dec 31, 2023 | 105 | 28 | 36.36% |
Dec 31, 2022 | 77 | -33 | -30.00% |
Dec 31, 2021 | 110 | 29 | 35.80% |
Dec 31, 2020 | 81 | 11 | 15.71% |
Dec 31, 2019 | 70 | 9 | 14.75% |
Dec 31, 2018 | 61 | -15 | -19.74% |
Dec 31, 2017 | 76 | 36 | 90.00% |
Dec 31, 2016 | 40 | 3 | 8.11% |
Dec 31, 2015 | 37 | 14 | 60.87% |
Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SMMT News
- 10 days ago - Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire
- 14 days ago - Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
- 17 days ago - What's Going On With Summit Therapeutics Stock On Friday? - Benzinga
- 17 days ago - Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China - Business Wire
- 18 days ago - Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025 - Business Wire
- 19 days ago - Why Is Summit Therapeutics Stock Soaring On Wednesday? - Benzinga
- 19 days ago - Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China - Business Wire